| HOME >> BIOLOGY >> TECHNOLOGY |
(3) In 2007, non-GAAP and GAAP net income included a non-recurring milestone of $40 million. The Company does not expect to achieve any material milestones in 2008.
(4) GAAP net income for 2008 is expected to include stock-based
compensation expense of approximately $30 million, amortization of
intangibles of $34 million, and restructuring charges of less than $5
million. There could be additional charges excluded from the Company's GAAP
net income, to arrive at non-GAAP net income, which are dependent on
unknown future events and are difficult to predict and estimate at this
time.
Contacts:
Kyle Kuvalanka (investors) Jennifer Snyder (media)
(617) 761-4734 (617) 444-1439
Millennium Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
Three Months Ended Year Ended
December 31, December 31,
2007 2006 2007 2006
(in thousands, except per share amounts)
Revenues:
Net product sales $73,691 $55,132 $265,241 $220,452
Revenue under strategic
alliances 57,249 48,685 95,417 131,675
Royalties 50,250 36,321 166,867 134,703
Total revenues 181,190 140,138 527,525 486,830
Costs and expenses:
Cost of sales 10,712 8,785 28,380 45,445
Research and development
(Note 1, 2) 76,362 80,868 287,094 310,910
Selling, general and
administrative (Note 1, 2) 53,126 50,371 189,062 162,893
Restructu
'/>"/>
| SOURCE Millennium Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |